21st Austria weekly - Marinomed 07/02/2024 [pic1]Marinomed: Biotech AG has enrolled the first patient in a clinical study to investigate lubricating properties of Carragelose eye drops patients diagnosed with mild moderate dry disease. While product holds valid certification under Medical Device Directive MDD supports switch new Regulation MDR. are planned launch 2024. Furthermore business development process for partnering outside is full swing. Next drops also allergen-blocking nasal spray published data demonstrating effectiveness prophylactic treatment allergic rhinitis symptoms nose on pre-print server October
21st Austria weekly - Marinomed Austrian Post 18/12/2023 [pic1]Marinomed: Marinomed Biotech AG considers strategic options for its Carragelose business and has mandated an external advisor. A structured process was initiated in which the advisor will start engaging with potential partners. This initiative meets attractive market environment those assets that comply new EU medical device regulation MDR. In May 2024 important interim period ends imposing challenging requirements all devices. Products don’t fulfil these lose their certificate must not be marketed. products necessary prerequisites MDR are backed by extensive clinical data comprising >1000 patients 12 international trials. is a unique patent-protected broadly active virus-blocking compound currently used marketed product portfolio prophylaxis treatment of viral respiratory infections. Recent data also support extension using Allergy Eye
EQSAdhoc Marinomed Biotech AG Key word Strategic Company Decision Marinomed Biotech AG evaluates strategic options for Carragelose portfolio 18Dec2023 0830 CETCEST Disclosure of an inside information
21st Austria weekly - Marinomed EVN 14/12/2023 [pic1]Marinomed: Marinomed Biotech AG has signed a licensing agreement with Favorex subsidiary of DKSH and part the Healthcare Business Unit to commercialize Carragelose nasal spray in Malaysia Myanmar Thailand Philippines. In addition European
21st Austria weekly - Marinomed Vienna Insurance Group 21/11/2023 [pic1]Marinomed: Marinomed Biotech AG recorded stable revenues of € 7.2 million in the first three quarters 2023 Q1-Q3 2022: 7.1 million due to continued demand for Carragelose virus blockers. The increase personnel costs higher R&D expenses and lower research subsidies were reflected operating result -4.4 -3.8 million. period amounted -5.6 million compared -5.8 prior-year period. For platform took necessary steps create an all-year product portfolio a expansion therapeutic area immunology with allergy blocker eye drops. market launches are already preparation 2024. Procter & Gamble also secured rights Carragelose-based spray USA. has paved way further important partnerships candidates Budesolv Tacrosolv which based on Marinosolv